Literature DB >> 17092530

The SIVmac239 Pr55Gag isoform, SIV p43, suppresses proteolytic cleavage of Pr55Gag.

Michael G Nicholson1, Sheila A Barber, Janice E Clements.   

Abstract

In human immunodeficiency virus type 1 (HIV-1) and simian immunodeficiency virus (SIV) the gag gene encodes the precursor polyprotein Pr55Gag, which is cleaved by the viral protease to produce the major structural proteins. Recently, it has been shown that HIV and SIV gag RNAs contain internal ribosome entry sites (IRESs) that mediate translation of Pr55Gag [Pr57Gag in HIV type 2 (HIV-2)] isoforms. Previously, we demonstrated that SIVmac239 p43(-), a mutant that does not express the Pr55Gag isoform, SIV p43, replicates more efficiently than wild-type (WT) SIVmac239 in cell culture. In this study, we characterize SIVmac239 p43(-) virion production and demonstrate that, in the absence of SIV p43, cleavage of Pr55Gag is increased in budded virions, resulting in a higher percentage of mature particles. Additionally, intracellular cleavage of Pr55Gag is increased in SIVmac239 p43(-), suggesting that SIV p43 suppresses premature cleavage of Pr55Gag by the viral protease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17092530      PMCID: PMC1855267          DOI: 10.1016/j.virol.2006.10.003

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  33 in total

1.  Phosphorylation and proteolytic cleavage of gag proteins in budded simian immunodeficiency virus.

Authors:  Sarah M Rue; Jason W Roos; Patrick M Tarwater; Janice E Clements; Sheila A Barber
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

2.  Characterization of ribosomal frameshifting in HIV-1 gag-pol expression.

Authors:  T Jacks; M D Power; F R Masiarz; P A Luciw; P J Barr; H E Varmus
Journal:  Nature       Date:  1988-01-21       Impact factor: 49.962

3.  Human immunodeficiency virus protease expressed in Escherichia coli exhibits autoprocessing and specific maturation of the gag precursor.

Authors:  C Debouck; J G Gorniak; J E Strickler; T D Meek; B W Metcalf; M Rosenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1987-12       Impact factor: 11.205

4.  HIV-2 genomic RNA contains a novel type of IRES located downstream of its initiation codon.

Authors:  Cécile H Herbreteau; Laure Weill; Didier Décimo; Déborah Prévôt; Jean-Luc Darlix; Bruno Sargueil; Théophile Ohlmann
Journal:  Nat Struct Mol Biol       Date:  2005-11       Impact factor: 15.369

5.  Incorporation of Pr160(gag-pol) into virus particles requires the presence of both the major homology region and adjacent C-terminal capsid sequences within the Gag-Pol polyprotein.

Authors:  M Huang; M A Martin
Journal:  J Virol       Date:  1997-06       Impact factor: 5.103

6.  The p2 domain of human immunodeficiency virus type 1 Gag regulates sequential proteolytic processing and is required to produce fully infectious virions.

Authors:  S C Pettit; M D Moody; R S Wehbie; A H Kaplan; P V Nantermet; C A Klein; R Swanstrom
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

7.  An internal ribosome entry site promotes translation of a novel SIV Pr55(Gag) isoform.

Authors:  Michael G Nicholson; Sarah M Rue; Janice E Clements; Sheila A Barber
Journal:  Virology       Date:  2006-02-21       Impact factor: 3.616

8.  Overexpression of human immunodeficiency virus type 1 protease increases intracellular cleavage of Gag and reduces virus infectivity.

Authors:  B G Luukkonen; E M Fenyö; S Schwartz
Journal:  Virology       Date:  1995-02-01       Impact factor: 3.616

9.  Active human immunodeficiency virus protease is required for viral infectivity.

Authors:  N E Kohl; E A Emini; W A Schleif; L J Davis; J C Heimbach; R A Dixon; E M Scolnick; I S Sigal
Journal:  Proc Natl Acad Sci U S A       Date:  1988-07       Impact factor: 11.205

10.  Molecular characterization of gag proteins from simian immunodeficiency virus (SIVMne).

Authors:  L E Henderson; R E Benveniste; R Sowder; T D Copeland; A M Schultz; S Oroszlan
Journal:  J Virol       Date:  1988-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.